LONG-TERM SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND BRCA MUTATIONS TREATED WITH OLAPARIB

In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive Olaparib or placebo for up to 2 years. After a 7-year follow-up, prespecified analysis of overall survival was reported. This is the longest follow-up of a …

LONG-TERM SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND BRCA MUTATIONS TREATED WITH OLAPARIB Read More »